Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04526886 · ADVERSE EVENTS

Adverse events

Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy · Source last updated 2025-10-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
Adverse event data were collected between the date of registration and the day 1 of the cycle 6 of FOLFOX chemotherapy (14-day planned cycle length).
Other-event reporting threshold
5%
Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
All Enrolled Participants

All participants enrolled in the study - includes participants who were not evaluable for the primary study outcome

0 / 524 / 521 / 52

Group identifiers: EG000: All Enrolled Participants

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    1. assessment Type
      SYSTEMATIC_ASSESSMENT
      organ System
      Blood and lymphatic system disorders
      stats
      1. group Id
        EG000
        num Affected
        4
        num At Risk
        52
        num Events
        4
      term
      Neutropenia, Grade 4
    Complete source fields
    event Groups
    1. deaths Num Affected
      1
      deaths Num At Risk
      52
      description
      All participants enrolled in the study - includes participants who were not evaluable for the primary study outcome
      id
      EG000
      other Num Affected
      4
      other Num At Risk
      52
      serious Num Affected
      0
      serious Num At Risk
      52
      title
      All Enrolled Participants
    frequency Threshold
    5
    other Events
    1. assessment Type
      SYSTEMATIC_ASSESSMENT
      organ System
      Blood and lymphatic system disorders
      stats
      1. group Id
        EG000
        num Affected
        4
        num At Risk
        52
        num Events
        4
      term
      Neutropenia, Grade 4
    time Frame
    Adverse event data were collected between the date of registration and the day 1 of the cycle 6 of FOLFOX chemotherapy (14-day planned cycle length).

    Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

    Preserved source evidence · Not medical advice